Advert - LEO Pharma – Case AUTH/3428/11/20

Use of LinkedIn


For LEO Pharma UK employees’ engagement with a number of posts on the global LinkedIn page, which resulted in multiple breaches of the Code including promoting a medicine prior to the grant of its marketing authorisation, promotion of Enstilar (betamethasone dipropionate/calcipotriol monohydrate) which was inconsistent with its marketing authorisation and misleading with respect to the safety of the medicine, LEO Pharma was ruled in breach of the following clauses of the 2019 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 3.1 - Promoting an unlicensed medicine
Clause 3.2 - Promotion inconsistent with the summary of product characteristics
Clause 4.1 - Failing to include prescribing information
Clause 4.8 - Failing to include the date on which the promotional material was drawn up or last revised.
Clause 7.2 - Making a misleading claim
Clause 7.9 - Making claims that did not reflect the available evidence regarding possible adverse reactions
Clause 9.1 - Failing to maintain high standards
Clause 14.1 - Failing to certify promotional material
Clause 14.3 - Failing to certify educational material for the public
Clause 26.1 - Promoting a prescription only medicine to the public